The New COVID-19 Treatments Add-on Payment will allow additional Medicare payment for eligible hospital inpatient and outpatient cases that involve certain new products or treatments authorized or approved for COVID-19.
The American Medical Association (AMA) recently announced a handful of new CPT® codes for reporting COVID-19 vaccine products and immunization administration. The code release includes two vaccine product codes and four vaccine administration codes.
CMS provided clarification on submitting inpatient claims for patients diagnosed with novel coronavirus (COVID-19) without a positive viral test, in an update to MLN Matters SE20015 released September 11.
CMS extended the education and operations testing period for the Appropriate Use Criteria (AUC) program for advanced diagnostic imaging through 2021. The education and operations testing period, which started January 1, 2020, was slated to close at the end of the year. Payment penalties were scheduled to go into effect January 1, 2021.
The AMA on August 10 announced four new CPT® codes for reporting COVID-19 laboratory testing, including two codes for reporting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody detection.
CMS’ latest round of updates to its novel coronavirus FAQs on Medicare fee-for-service billing provides additional information on hospital billing for remote services, including a decision tree guiding hospitals through their options for billing for telemedicine.
The guidelines are effective October 1 and highlights include new instructions for reporting manifestations of novel coronavirus (COVID-19), vaping, and social determinants of health among other changes.
A federal judge dismissed the American Hospital Association’s challenge to CMS' Hospital Price Transparency Requirements final rule. The final rule, effective January 1, 2021, will require hospitals to disclose charges they privately negotiate with commercial payers, among other requirements.
